ClearCut Medical · raw details

ClearCut Medical develops and commercializes solutions designed for the accurate and effective removal of cancer. Its technology is based on magnetic resonance imaging (MRI) protocols that enable accurate and rapid surface imaging for real-time margin assessment of excised tissue in the operating room. The companys ClearSight MRI System is focused on breast cancer lumpectomies, enabling an intraoperative margin assessment of surgically removed lumps. The system is expected to significantly improve surgical outcomes and reduce re-excision rates. Future applications include prostate and breast cancer biopsies and skin cancer excisions, as well as additional oncological applications, including colorectal and lung cancers. The device is CE marked and has shown industry-leading accuracy in comparison to histopathology in two multi-center trials. ClearCut Medical is initially focusing on breast-conserving surgery, with a TAM of $1.2 billion in the U.S. and Europe. In March 2018, the Australian Department of Healths Therapeutic Goods Administration (TGA) issued a Therapeutic Goods Certificate for the ClearSight MRI System. ClearCut Medicals distribution partner, Surgeon Choice Australia Pty Ltd, will supply the product to key surgical cancer centers in Australia.